By region, the global human combination vaccines market is segmented into North America, Europe, Asia, and Rest of World (ROW). North America will account for 45% of market growth during the forecast period. Factors such as the continuous efforts by vendors and national organizations to promote the use of human combination vaccines and strict regulatory norms that recommend the proper vaccination of infants are driving the growth of the human combination vaccines market in North America. Buy the report
Company Profiles
The human combination vaccines market report includes information on the key products and recent developments of leading vendors, including:
Abbott Laboratories - The company offers human combination vaccines such as Enteroshield, Influvac vaccine 2014, Influvac Jr vaccine, Rotasure, and Pentashield.
Bharat Biotech Ltd. - The company offers human combination vaccine named BioHib vaccine for various purposes.
Biological E. Ltd. - The company offers human combination vaccine namely, Pneumococcal Conjugate Vaccine and DTwP Hib Vaccine which are in phase 2 study.
Cadila Healthcare Ltd. - The company offers human combination vaccines such as Human Papilloma Virus, Leishmaniasis, Malaria, Haemorrhagic Congo Fever, Ebola, and Japanese Encephalitis.
Market Dynamics
The market is driven by factors such as increasing antiviral drug resistance, increase in pediatric population, and rise in cases of infectious diseases. However, the incompatibility of vaccine components is hindering the market growth.
Competitive Analysis
The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share among others. Request a Sample
Market Segmentation
By type, the market is segmented into inactivated vaccine and live attenuated vaccine. The inactivated vaccine segment accounted for the largest share of the market in 2022.
By geography, the market is segmented into North America, Europe, Asia, and Rest of World (ROW). North America held the largest share of the market in 2022.
Related Reports:
The mono vaccine market size is expected to increase by USD 2.8 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.16%. The increase in the pediatric population is one of the key factors driving the global mono vaccine market growth. The challenges associated with the development, storage, and handling of vaccines are the major challenge to the global mono vaccine market growth.
The narcolepsy drugs market size is expected to increase to USD 1.60 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 9.1%. The rising product launches and clinical trials is notably driving the narcolepsy drugs market growth, although factors such as lack of awareness may impede the market growth.
What are the key data covered in this human combination vaccines market report?
CAGR of the market during the forecast period.
Detailed information on factors that will drive the growth of the market between 2023 and 2027
Precise estimation of the size of the human combination vaccines market and its contribution to the parent market.
Accurate predictions about upcoming trends and changes in consumer behavior.
Growth of the market across North America, Europe, Asia, and Rest of World (ROW).
A thorough analysis of the market's competitive landscape and detailed information about vendors.
Comprehensive analysis of factors that will challenge the growth of human combination vaccines market vendors.
Human Combination Vaccines Market Scope
Report Coverage
Details
Page number
168
Base year
2022
Historic period
2017-2021
Forecast period
2023-2027
Growth momentum & CAGR
Accelerate at a CAGR of 8.13%
Market growth 2023-2027
USD 6046.98 million
Market structure
Concentrated
YoY growth 2022-2023 (%)
7.45
Regional analysis
North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution
North America at 45%
Key countries
US, Canada, UK, Germany, and Japan
Competitive landscape
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled
Abbott Laboratories, Arabio, Bharat Biotech Ltd., Biological E. Ltd., Cadila Healthcare Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Grifols SA, LG Corp., Meiji Holdings Co. Ltd., Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Panacea Biotec Ltd., Pfizer Inc., PT Bio Farma, Sanofi SA, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., and Walvax Biotechnology Co. Ltd.
Market dynamics
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.
Customization purview
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Table of contents:
1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary ? Chart on Market Overview
Exhibit 02: Executive Summary ? Data Table on Market Overview
Exhibit 03: Executive Summary ? Chart on Global Market Characteristics
Exhibit 04: Executive Summary ? Chart on Market by Geography
Exhibit 05: Executive Summary ? Chart on Market Segmentation by Type
Exhibit 06: Executive Summary ? Chart on Market Segmentation by Channel
Exhibit 07: Executive Summary ? Chart on Incremental Growth
Exhibit 08: Executive Summary ? Data Table on Incremental Growth
Exhibit 09: Executive Summary ? Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
4.1 Global human combination vaccines market 2017 - 2021
Exhibit 18: Historic Market Size ? Data Table on Global human combination vaccines market 2017 - 2021 ($ million)
Exhibit 152: Merck and Co. Inc. - Business segments
Exhibit 153: Merck and Co. Inc. - Key news
Exhibit 154: Merck and Co. Inc. - Key offerings
Exhibit 155: Merck and Co. Inc. - Segment focus
12.14 Mitsubishi Chemical Holdings Corp.
Exhibit 156: Mitsubishi Chemical Holdings Corp. - Overview
Exhibit 157: Mitsubishi Chemical Holdings Corp. - Business segments
Exhibit 158: Mitsubishi Chemical Holdings Corp. - Key offerings
Exhibit 159: Mitsubishi Chemical Holdings Corp. - Segment focus
12.15 Pfizer Inc.
Exhibit 160: Pfizer Inc. - Overview
Exhibit 161: Pfizer Inc. - Product / Service
Exhibit 162: Pfizer Inc. - Key news
Exhibit 163: Pfizer Inc. - Key offerings
12.16 Sanofi SA
Exhibit 164: Sanofi SA - Overview
Exhibit 165: Sanofi SA - Business segments
Exhibit 166: Sanofi SA - Key news
Exhibit 167: Sanofi SA - Key offerings
Exhibit 168: Sanofi SA - Segment focus
12.17 Serum Institute of India Pvt. Ltd.
Exhibit 169: Serum Institute of India Pvt. Ltd. - Overview
Exhibit 170: Serum Institute of India Pvt. Ltd. - Product / Service
Exhibit 171: Serum Institute of India Pvt. Ltd. - Key offerings
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 172: Inclusions checklist
Exhibit 173: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 174: Currency conversion rates for US$
13.4 Research methodology
Exhibit 175: Research methodology
Exhibit 176: Validation techniques employed for market sizing
Exhibit 177: Information sources
13.5 List of abbreviations
Exhibit 178: List of abbreviations
About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
As the world eagerly anticipates advancements in diagnostics, Biolabs International LLC stands at the forefront of innovation with the announcement of an exclusive distribution agreement. In response to the unprecedented demand for the highly...
Market Cap : US$3,975.7 million*Note: For the figures included in the FFSS, the Company has accounted for the effects of inflation adjustment adopted by Resolution 777/18 of the Comisión Nacional de Valores ("CNV"), which establishes...
Swiss Water Decaffeinated Coffee Inc. ("Swiss Water" or "the Company"), a leading specialty coffee company and premium green coffee decaffeinator, today reported financial results for the three months ended March 31, 2024....
Sangoma Technologies Corporation ("Sangoma" or the "Company"), a trusted leader in delivering cloud-based Communications as a Service solutions for companies of all sizes, today announced its third quarter financial results and unaudited condensed...
Manulife Financial Corporation ("Manulife" or the "Company") reported its first quarter results for the period ended March 31, 2024, delivering strong core ROE and topline growth, and closing the largest long-term care ("LTC") reinsurance transaction...
BSR Real Estate Investment Trust ("BSR", or the "REIT") today announced its financial results for the three months ended March 31, 2024 ("Q1 2024"). All comparisons are to the corresponding periods in the prior year. Results are presented in U.S....